ZVSA
ZyVersa Therapeutics, Inc.
0.00 (0.00%)0.10USD3.8K成交股數801K市值–本益比(近四季)–股價營收比+10.8%營收年增(近四季)2026-09-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | −133K-4% | −131K-0% | −130K+224100% | −120K+118275% | −138K+65644% | −132K+41822% | −58.00-105% | −101.00 | −210.00 | −314.00 | 1K | – |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 58K | 365K | 410K | 259K | 121K | 436K | 709K | 513K | 674K | 1.2M | 1.1M | 400K |
| 銷售管理費用 | 1.2M | 1.7M | 1.6M | 1.9M | 1.2M | 1.8M | 2.0M | 2.3M | 2.2M | 3.9M | 3.5M | 420K |
| 營業利益 | −1.3M+1% | −20.8M+814% | −2.0M-26% | −2.1M-24% | −1.3M-56% | −2.3M-97% | −2.8M-40% | −2.8M+245% | −2.9M | −86.3M | −4.6M | −820K |
| 營業利益率 | 984.6% | 15,799.1% | 1,572.0% | 1,793.7% | 931.9% | 1,724.2% | 4,748,237.9% | 2,798,649.5% | 1,382,227.6% | 27,492,039.8% | -425,981.4% | – |
| 稅後淨利 | −1.8M+26% | −19.8M+725% | −2.2M-20% | −2.3M-20% | −1.4M-51% | −2.4M-97% | −2.8M-22% | −2.8M+3668% | −2.9M | −78.5M | −3.5M | −75K |
| 淨利率 | 1,353.4% | 15,078.5% | 1,700.5% | 1,887.7% | 1,029.8% | 1,824.2% | 4,765,074.1% | 2,798,749.5% | 1,382,096.7% | 25,004,169.7% | -328,752.3% | – |
| 稀釋 EPS | -0.22-112% | -2.56+5% | -0.46-86% | -0.73-84% | 1.79-106% | -2.43-100% | -3.31-98% | -4.53+1462% | -30.18 | -1694.12 | -135.88 | -0.29 |
| 稀釋股數 | 8.1M | 7.7M | 4.8M | 3.1M | 1.1M | 988K | 835K | 624K | 97.3K | 51.0K | 26.1K | 258K |
資產負債表 期末餘額
| 科目 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 303K | 528K | 72K | 1.6M | 1.5M | 123K | 119K | 2.0M | 1.6M | 229K | 1.3M | 5.9M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 742K | 1.0M | 19.6M | 21.0M | 20.6M | 19.4M | 19.5M | 21.7M | 32.9M | 32.0M | 115M | 119M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 14.9M | 12.8M | 13.5M | 12.9M | 12.1M | 12.4M | 10.8M | 10.4M | 13.1M | 11.9M | 17.9M | 18.5M |
| 股東權益 | −14.1M | −11.7M | 6.1M | 8.1M | 8.5M | 7.0M | 8.6M | 11.2M | 19.7M | 20.1M | 97.1M | 99.7M |
| 負債比 | 2,003.0% | 1,227.2% | 68.9% | 61.3% | 58.7% | 63.8% | 55.7% | 48.2% | 40.0% | 37.3% | 15.5% | 15.6% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 | 22Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | −799K | – | – | −1.8M-53% | – | – | – | −3.8M+11% | – | – | −4.6M | −3.4M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | −513K | +90.2% | −25.0M | 4,862.0% | -4.18 | – |
| FY2024 | −270K | -59149.5% | −9.4M | 3,488.3% | -8.48 | – |
| FY2023 | 457.00 | -100.1% | −98.3M | -21,509,397.4% | -1089.70 | – |
| FY2022 | −428K | – | −14.0M | 3,285.7% | -0.99 | – |